Aarti Pharmalabs Ltd

- The transcript does not mention any current or future plans for fundraising through debt or equity. - There is no discussion of new debt issuance or equity offerings during the Q2 FY26 earnings call. - The company focuses on operational updates, capacity expansions (Atali plant, Xanthine expansion), and growth guidance. - Financial discipline and long-term customer relationships are emphasized as pillars of progress, suggesting a preference for organic growth. - No statements indicate plans to raise capital via market instruments in the near future.

- Atali plant: INR 450 crore CAPEX, inaugurated in September 2025, started operations with trial batches; expected to be fully operational in 2-3 quarters (by FY '27) to contribute meaningfully to revenue. - Xanthine expansion: Capacity increased from 5,000 to 9,000 metric tons (annual installed capacity) by end of FY '26; expansion is brownfield with phased operationalization. - Facility upgrades: Focus on debottlenecking and standardizing production, including at Ganesh Polychem to improve cost efficiency and profitability. - Site shifting plan: Future plan to shift Dombivli site within the year as part of strategic operational improvements. - Ongoing R&D and capacity capitalization: Some projects still under capital work-in-progress (WIP), with more capitalization expected towards year-end. - Expansion supports future growth, especially in Intermediate and CDMO-CMO business segments.

- CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth. - New molecules moving from development to commercial phase will drive sales, with larger growth anticipated in FY '27 and beyond. - API business to normalize and ramp up in H2 FY '26 after inventory corrections and product mix optimization, including oncology and steroid APIs, with major launches in FY '27 and FY '28. - Atali plant will become fully operational in 2-3 quarters, boosting Intermediate and CDMO business revenue from FY '27 onward. - Xanthine capacity expansion to 9,000 tons/year by end of FY '26, with gradual ramp-up over 2-3 years expected to capture ~25% market share. - Long-term target of INR 1,000 crore revenue from CDMO side in 2-3 years considered achievable. - Overall EBITDA growth guidance is 8%-12% for FY '26, with a longer-term goal of 15%-20% EBITDA growth over 3 years.

- FY '26 EBITDA growth guidance revised to 8%-12% year-on-year, despite challenges (Page 4). - Long-term target remains 15%-20% EBITDA growth over the next 2-3 years, subject to new product launches and market conditions (Page 14). - CDMO segment expected to exceed earlier 30%-40% growth guidance this year, with substantial sales growth in H2 (Page 14). - Ganesh Polychem losses expected to reduce, with profitability stabilizing near FY '25 levels by FY '27 (Page 20). - API segment growth challenging in short-term due to inventory correction but expected to rebound with new oncology launches in FY '27 and FY '28 (Page 11). - Atali plant to become fully operational by FY '27 contributing meaningfully to revenue (Page 5). - Overall, management expects recovery and reasonable profit growth from FY '27 onwards after a rough FY '26 (Page 25).

- The CDMO-CMO segment currently has 59 active projects, with 39 in the commercial stage and 20 under various stages of development at the customer's end. - The company is working with 21 customers in this segment and is on track to achieve and exceed the earlier estimated sales target of 30% to 40% Y-o-Y growth. - Management is actively participating in several RFPs (Requests for Proposals) to increase the CDMO project funnel, including expanding geographical presence in Europe and North America to boost business development. - New product commercializations and approvals over recent quarters have led to enhanced visibility and long-term potential order book growth. - Expansion and capacity debottlenecking, particularly in the Xanthine segment and Atali facility, indicate readiness to fulfill growing orders, with full operational capacity expected in 2-3 quarters for Atali and Xanthine capacity expected to ramp up to 9,000 MT by year-end.